|
Madhusudan V. Peshwa PhD
Chief Technology Officer, Cell Therapy
Cell Therapy Tessera Therapeutics
USA
|
Madhusudan V. Peshwa, Ph.D., serves as Chief Technology Officer, Cell Therapy, for Tessera
Therapeutics. Dr. Peshwa joined Tessera in May 2021 and is responsible for developing the
strategy and executing the operating plan encompassing the design, development and
manufacture of Tessera’s proprietary mobile gene element engineered cell therapy product
portfolio.
Recently, in March 2020, Dr. Peshwa was inducted into the College of Fellows at the American
Institute for Medical and Biological Engineering (AIMBE), in recognition of contributions in
Regenerative Medicine to advancements in the field of cell & gene therapies.
Prior to joining Tessera, Dr. Peshwa was CTO at Mana Therapeutics, an immunotherapy
company focused on the development of allogeneic, multi-tumor-antigen-targeted, nonengineered, T-cell immunotherapies with additional oversight of Quality Assurance and Quality
Control functions. Previously, Dr. Peshwa was CTO and Global Head of R&D for the Cell and
Gene Therapies business at GE Healthcare (GEHC), with responsibilities that include GEHC’s CGT
product and service portfolio to enable and accelerate the development of robust, scalable,
industrialized manufacturing and delivery of cell and gene therapies. Prior to these roles, Dr.
Peshwa held various executive positions at MaxCyte, Inc., NewNeural LLC, and Dendreon
Corporation. At MaxCyte, as CSO and EVP, Cellular Therapies, Dr. Peshwa was responsible for
leading the development and commercialization of ex vivo cell loading platform technology.
Additionally, he also established MaxCyte’s proprietary therapeutic product portfolio with lead
program being a non-viral mRNA engineered CAR Immunotherapy (CARMA) with one-day
manufacturing process under company sponsored IND for treatment of solid cancers; and
additional collaborative programs under CRADA Agreement with Investigators at NIAID and
NHLBI, for ex vivo gene correction in autologous hematopoietic stem cells, as cell therapy for
potential treatment of monogenic diseases. As Vice President of Process Sciences and
Manufacturing, at Dendreon Corporation, Dr. Peshwa was responsible for leading the CMC and
GMP manufacturing for Provenge® (Sipuleucel-T), an autologous cellular immunotherapy
product for treatment of prostate cancer, the first ever active cellular immunotherapy product
approved by the US FDA.
In addition to his broad industry experience, Dr. Peshwa has served as Principal Investigator /
Co-Investigator on multiple grant-funded research studies, is an inventor of seven issued US
patents in the field of cell therapy, and has served in various consultative, advisory, and board
capacities to industry, government, not-for-profit, and financial organizations. Dr. Peshwa
earned his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in
Chemical Engineering from the Indian Institute of Technology in Kanpur, India.
Therapeutics. Dr. Peshwa joined Tessera in May 2021 and is responsible for developing the
strategy and executing the operating plan encompassing the design, development and
manufacture of Tessera’s proprietary mobile gene element engineered cell therapy product
portfolio.
Recently, in March 2020, Dr. Peshwa was inducted into the College of Fellows at the American
Institute for Medical and Biological Engineering (AIMBE), in recognition of contributions in
Regenerative Medicine to advancements in the field of cell & gene therapies.
Prior to joining Tessera, Dr. Peshwa was CTO at Mana Therapeutics, an immunotherapy
company focused on the development of allogeneic, multi-tumor-antigen-targeted, nonengineered, T-cell immunotherapies with additional oversight of Quality Assurance and Quality
Control functions. Previously, Dr. Peshwa was CTO and Global Head of R&D for the Cell and
Gene Therapies business at GE Healthcare (GEHC), with responsibilities that include GEHC’s CGT
product and service portfolio to enable and accelerate the development of robust, scalable,
industrialized manufacturing and delivery of cell and gene therapies. Prior to these roles, Dr.
Peshwa held various executive positions at MaxCyte, Inc., NewNeural LLC, and Dendreon
Corporation. At MaxCyte, as CSO and EVP, Cellular Therapies, Dr. Peshwa was responsible for
leading the development and commercialization of ex vivo cell loading platform technology.
Additionally, he also established MaxCyte’s proprietary therapeutic product portfolio with lead
program being a non-viral mRNA engineered CAR Immunotherapy (CARMA) with one-day
manufacturing process under company sponsored IND for treatment of solid cancers; and
additional collaborative programs under CRADA Agreement with Investigators at NIAID and
NHLBI, for ex vivo gene correction in autologous hematopoietic stem cells, as cell therapy for
potential treatment of monogenic diseases. As Vice President of Process Sciences and
Manufacturing, at Dendreon Corporation, Dr. Peshwa was responsible for leading the CMC and
GMP manufacturing for Provenge® (Sipuleucel-T), an autologous cellular immunotherapy
product for treatment of prostate cancer, the first ever active cellular immunotherapy product
approved by the US FDA.
In addition to his broad industry experience, Dr. Peshwa has served as Principal Investigator /
Co-Investigator on multiple grant-funded research studies, is an inventor of seven issued US
patents in the field of cell therapy, and has served in various consultative, advisory, and board
capacities to industry, government, not-for-profit, and financial organizations. Dr. Peshwa
earned his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in
Chemical Engineering from the Indian Institute of Technology in Kanpur, India.